Building a Genetics Engine to Crack the Target Bottleneck
About this episode
Aris Baras discusses how Regeneron is using genetics and AI to improve drug discovery.
A chronic shortage of high‑quality targets remains one of the biggest constraints in drug discovery, even as therapeutic tools become more powerful and diverse. Regeneron is tackling that problem with its Regeneron Genetics Center, which has built a genetics‑driven discovery engine that integrates human genetics with rich clinical data, large‑scale proteomics, and AI‑driven analytics. Aris Baras, head of the Regeneron Genetics Center, discusses how proteomics is reshaping RGC’s view of risk prediction, how AI helps his team sift through hundreds of millions of variants, and what it really takes to scale this kind of effort and translate it into more successful, transformative therapies for patients.
People in this episode
Guest: Aris Baras
Topics covered
- drug discovery
- genetics
- proteomics
- AI analytics
- therapeutic tools
Keywords
- drug discovery
- genetics
- proteomics
- AI
- risk prediction
- therapies
- clinical data
Mentioned in this episode
Organizations: Regeneron, Regeneron Genetics Center
More episodes of The Bio Report
- Addressing a Data Problem to Enable AI-Drug Discovery
- Turning Multi Specific Antibody Design into an Engineering Discipline with AI
- Addressing the Treatment Gap in Ischemic Stroke
- A Pipeline in a Product that Reimagines Control of Inflammation
Explore listener stats, chart rankings, contacts and more on the The Bio Report podcast page.